Qualitative and Quantitative Analysis of MR Imaging Findings in Patients with Middle Cerebral Artery Stroke Implanted with Mesenchymal Stem Cells

References

1. 1.↵
   2. Roger VL,
   3. Go AS,
   4. Lloyd-Jones DM, et al

   ; for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2012 update—a report from the American Heart Association. Circulation 2012;125:e2–220

   FREE Full Text
2. 2.↵
   2. Johnston SC,
   3. Mendis S,
   4. Mathers CD

   . Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol 2009;8:345–54

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Adeoye O,
   3. Hornung R,
   4. Khatri P, et al

   . Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011;42:1952–55

   Abstract/FREE Full Text
4. 4.↵
   2. Hong KS,
   3. Ali LK,
   4. Selco SL, et al

   . Weighting components of composite end points in clinical trials: an approach using disability-adjusted life-years. Stroke 2011;42:1722–29

   Abstract/FREE Full Text
5. 5.↵
   2. Friedrich MA,
   3. Martins MP,
   4. Araújo MD, et al

   . Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant 2012;21(suppl 1):S13–21

   CrossRefPubMed
6. 6.↵
   2. Lee JS,
   3. Hong JM,
   4. Moon GJ, et al

   . A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010;28:1099–106

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Honmou O,
   3. Houkin K,
   4. Matsunaga T, et al

   . Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011;134(pt 6):1790–807

   Abstract/FREE Full Text
8. 8.↵
   2. Bhasin A,
   3. Srivastava MV,
   4. Mohanty S, et al

   . Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg 2013;115:1003–08

   CrossRefPubMed
9. 9.↵
   2. Glover LE,
   3. Tajiri N,
   4. Weinbren NL, et al

   . A step-up approach for cell therapy in stroke: translational hurdles of bone marrow-derived stem cells. Transl Stroke Res 2012;3:90–98

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Mezey E,
    3. Chandross KJ,
    4. Harta G, et al

    . Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 2000;290:1779–82

    Abstract/FREE Full Text
11. 11.↵
    2. Phinney DG,
    3. Prockop DJ

    . Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views. Stem Cells 2007;25:2896–902

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Mohal JS,
    3. Tailor HD,
    4. Khan WS

    . Sources of adult mesenchymal stem cells and their applicability for musculoskeletal applications. Curr Stem Cell Res Ther 2012;7:103–09

    CrossRefPubMed
13. 13.↵
    2. Ikegame Y

    . Among mesenchymal stem cells: for the best therapy after ischemic stroke. Stem Cell Res Ther 2013;4:9

    CrossRefPubMed
14. 14.↵
    2. Tatarishvili J,
    3. Oki K,
    4. Monni E, et al

    . Human induced pluripotent stem cells improve recovery in stroke-injured aged rats. Restor Neurol Neurosci 2014;32:547–58

    PubMed
15. 15.↵
    2. Tornero D,
    3. Wattananit S,
    4. Grønning Madsen M, et al

    . Human induced pluripotent stem cell-derived cortical neurons integrate in stroke-injured cortex and improve functional recovery. Brain 2013;136(pt 12):3561–77

    Abstract/FREE Full Text
16. 16.↵
    2. Burns TC,
    3. Steinberg GK

    . Stem cells and stroke: opportunities, challenges and strategies. Expert Opin Biol Ther 2011;11:447–61

    CrossRefPubMed
17. 17.↵
    2. Bang OY,
    3. Lee JS,
    4. Lee PH, et al

    . Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005;57:874–82

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Hao L,
    3. Zou Z,
    4. Tian H, et al

    . Stem cell-based therapies for ischemic stroke. Biomed Res Int 2014;2014:468748

    PubMed
19. 19.↵
    2. Bao X,
    3. Feng M,
    4. Wei J, et al

    . Transplantation of Flk-1+ human bone marrow-derived mesenchymal stem cells promotes angiogenesis and neurogenesis after cerebral ischemia in rats. Eur J Neurosci 2011;34:87–98

    CrossRefPubMed
20. 20.↵
    2. Li J,
    3. Zhu H,
    4. Liu Y, et al

    . Human mesenchymal stem cell transplantation protects against cerebral ischemic injury and upregulates interleukin-10 expression in Macaca fascicularis. Brain Res 2010;1334:65–72

    CrossRefPubMed
21. 21.↵
    2. Smith SM,
    3. De Stefano N,
    4. Jenkinson M, et al

    . Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25:466–75

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Smith SM,
    3. Zhang Y,
    4. Jenkinson M, et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89

    CrossRefPubMedWeb of Science
23. 23.↵
    2. de Bresser J,
    3. Portegies M,
    4. Leemans A, et al

    . A comparion of MR based segmentation methods for measuring brain atrophy progression. Neuroimage 2011;54:760–68

    CrossRefPubMed
24. 24.↵
    2. Durand-Dubief F,
    3. Belaroussi B,
    4. Armspach JP, et al

    . Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques. AJNR Am J Neuroradiol 2012;33:1918–24

    Abstract/FREE Full Text
25. 25.↵
    2. Hall WA

    . The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer 1998;82:1749–55

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Eckert MA,
    3. Vu Q,
    4. Xie K, et al

    . Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke. J Cereb Blood Flow Metab 2013;33:1322–34

    CrossRefPubMed
27. 27.↵
    2. Aldahmash A,
    3. Atteya M,
    4. Elsafadi M, et al

    . Teratoma formation in immunocompetent mice after syngeneic and allogeneic implantation of germline capable mouse embryonic stem cells. Asian Pac J Cancer Prev 2013;14:5705–11

    CrossRefPubMed
28. 28.↵
    2. Yamamoto M,
    3. Cui L,
    4. Johkura K, et al

    . Branching ducts similar to mesonephric ducts or ureteric buds in teratomas originating from mouse embryonic stem cells. Am J Physiol Renal Physiol 2006;290:F52–60

    Abstract/FREE Full Text
29. 29.↵
    2. Inoue S,
    3. Popp FC,
    4. Koehl GE, et al

    . Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006;81:1589–95

    CrossRefPubMedWeb of Science
30. 30.↵
    2. François M,
    3. Romieu-Mourez R,
    4. Stock-Martineau S, et al

    . Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 2009;114:2632–38

    Abstract/FREE Full Text
31. 31.↵
    2. Ren G,
    3. Su J,
    4. Zhang L, et al

    . Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009;27:1954–62

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Ma S,
    3. Xie N,
    4. Li W, et al

    . Immunobiology of mesenchymal stem cells. Cell Death Differ 2014;21:216–25

    CrossRefPubMed
33. 33.↵
    2. Liu X,
    3. Ye R,
    4. Yan T, et al

    . Cell based therapies for ischemic stroke: from basic science to bedside. Prog Neurobiol 2014;115:92–115

    CrossRefPubMed
34. 34.↵
    2. Turc G,
    3. Aguettaz P,
    4. Ponchelle-Dequatre N, et al

    . External validation of the MRI-DRAGON score: early prediction of stroke outcome after intravenous thrombolysis. PLoS One 2014;9:e99164

    CrossRefPubMed
35. 35.↵
    2. Yoo AJ,
    3. Chaudhry ZA,
    4. Nogueira RG, et al

    . Infarct volume is a pivotal biomarker after intra-arterial stroke therapy. Stroke 2012;43:1323–30

    Abstract/FREE Full Text